Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $522.5 million.

  • Nurix Therapeutics' Liabilities and Shareholders Equity rose 1.73% to $522.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $2.4 billion, marking a year-over-year increase of 41.67%. This contributed to the annual value of $669.3 million for FY2024, which is 88.23% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Liabilities and Shareholders Equity of $522.5 million as of Q3 2025, which was down 11.68% from $591.6 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Liabilities and Shareholders Equity peaked at $669.3 million during Q4 2024, and registered a low of $308.2 million during Q3 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $465.5 million, with a median of $511.0 million in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 32.90% in 2023, then surged by 96.70% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $476.8 million in 2021, then decreased by 12.59% to $416.8 million in 2022, then fell by 14.68% to $355.6 million in 2023, then spiked by 88.23% to $669.3 million in 2024, then grew by 1.73% to $522.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $522.5 million in Q3 2025, compared to $591.6 million in Q2 2025 and $615.0 million in Q1 2025.